| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8518746 | Phytomedicine | 2017 | 26 Pages |
Abstract
This review summarized the successfull in vitro and in vivo studies showing that this combination approach of triterpene glycosides co-adminitered with anticancer, antimicrobial and anti-inflammatory drug may provide an exciting road for further developments in the treatment of some cancers, parasitic and inflammatory diseases and in the rational design of vaccines against infectious diseases and cancer. From a clinical point of view, the potential benefit of QS-21, a promising triterpene glycoside from Quillaja saponaria has been highlighted in several vaccine clinical trials with a favorable ratio efficacy/toxicity.
Keywords
MTBMICBCGAβArabinoseGlcEMAKLHQS-21APCFucoseFucMPLAPIGSKCTLLPSEGFRSaponaria officinalisLPXarabinofuranoseXylEGFTNF αMDRVZVRHAINF-γP-gpGlaxoSmithKlinenatural killerISCOMsP-glycoproteinamyloid βAntigen presenting cellsApioseEuropean Medicine AgencyAdjuvantGlucuronic acidAIDSImmunoglobulineinterferon-gammainterleukinBacille Calmette GuerinArafAlzheimer's diseaseTriterpene glycosidestumor necrosis factor αchimeric toxinMinimum inhibitory concentrationARArhamnoseHerpes zosterSubunitCancerNSCLChelper T cellsTH cellsacquired immune deficiency syndromeQuillaja saponariaadjuvant SystemAnti-inflammatoryepidermal growth factorCytotoxic T lymphocyteslipopolysaccharideAntimicrobialmajor histocompatibility complexMHCMultidrug-resistantNitric oxideVaccinesHIVhuman immunodeficiency virusVaricella zoster virusRIPRibosome inactivating proteinnon-small cell lung carcinomahigh performance liquid chromatographyHPLCkeyhole limpet hemocyaninCommittee for Medicinal Products for Human UseGalGalactoseXyloseGlucoseGlycoproteinEpidermal growth factor receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Marie-Aleth Lacaille-Dubois, Hildebert Wagner,